- The FDA has signed off on Vanda Pharmaceuticals' (NASDAQ:VNDA) IND for VSJ-110, a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) activator, for the potential treatment of an eye inflammation condition called allergic conjunctivitis.
- A Phase 2 study evaluating the candidate in volunteers in an ocular allergic challenge model is next up.
- The company in-licensed exclusive global rights to the asset in 2017 from the University of California San Francisco.
- https://seekingalpha.com/news/3626010-vanda-pharma-on-go-mid-stage-allergic-conjunctivitis-study
Monday, October 26, 2020
Vanda Pharma on go with mid-stage allergic conjunctivitis study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.